Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 71

Related Citations for PubMed (Select 24757362)

1.

Pharmaceutical approval update.

Goldenberg MM.

P T. 2014 Apr;39(4):262-96.

2.

Tasimelteon (Hetlioz tm ): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.

Bonacci JM, Venci JV, Gandhi MA.

J Pharm Pract. 2014 Aug 3. pii: 0897190014544792. [Epub ahead of print]

PMID:
25092604
3.

Pharmaceutical approval update.

Goldenberg MM.

P T. 2014 Jan;39(1):37-9.

4.

Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group.

Hilgartner M, Aledort L, Andes A, Gill J.

Transfusion. 1990 Sep;30(7):626-30.

PMID:
2402777
5.

Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.

Parmar S, Patel K, Pinilla-Ibarz J.

P T. 2014 Jul;39(7):483-519.

6.

Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.

Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, Klerman EB.

Lancet. 2009 Feb 7;373(9662):482-91. doi: 10.1016/S0140-6736(08)61812-7. Epub 2008 Dec 4. Erratum in: Lancet. 2009 Apr 11;373(9671):1252.

PMID:
19054552
7.

Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.

Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, Cortesi P, Jo H, Kavakli K, Lassila R, Morfini M, Négrier C, Rocino A, Schramm W, Serban M, Uscatescu MV, Windyga J, Zülfikar B, Mantovani L.

N Engl J Med. 2011 Nov 3;365(18):1684-92. doi: 10.1056/NEJMoa1104435. Erratum in: N Engl J Med. 2011 Dec 22;365(25):2441.

8.

FEIBA safety profile in multiple modes of clinical and home-therapy application.

Luu H, Ewenstein B.

Haemophilia. 2004 Sep;10 Suppl 2:10-6. Review.

PMID:
15385041
9.

A retrospective postlicensure survey of FEIBA efficacy and safety.

Dimichele D, Négrier C.

Haemophilia. 2006 Jul;12(4):352-62.

PMID:
16834734
11.
12.

FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations.

Perry D, Berntorp E, Tait C, Dolan G, Holme PA, Laffan M, Lassila R, Mumford A, Pasi J, Wilde J, Will A, Yee TT.

Haemophilia. 2010 Jan;16(1):80-9. doi: 10.1111/j.1365-2516.2009.02104.x. Epub 2009 Sep 23.

PMID:
19780845
13.

Pharmaceutical approval update.

Goldenberg MM.

P T. 2008 May;33(5):299-302.

14.

Monitoring the bioavailability of FEIBA with a thrombin generation assay.

Váradi K, Negrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, Linari S, Schwarz HP, Turecek PL.

J Thromb Haemost. 2003 Nov;1(11):2374-80.

PMID:
14629472
15.

The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.

Molica S.

Expert Rev Hematol. 2013 Oct;6(5):543-6. doi: 10.1586/17474086.2013.831324. Epub 2013 Oct 2.

PMID:
24083545
16.

Long-term FEIBA prophylaxis does not prevent progression of existing joint disease.

Hilgartner MW, Makipernaa A, Dimichele DM.

Haemophilia. 2003 May;9(3):261-8.

PMID:
12694515
17.
18.

The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.

Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, van Geijlswijk JL, van Houwelingen H, van Asten P, Sixma JJ.

N Engl J Med. 1981 Sep 24;305(13):717-21.

PMID:
6790990
19.

Pharmaceutical approval update.

Gohil K.

P T. 2015 Jan;40(1):33-5.

20.

Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia.

Chavez JC, Sahakian E, Pinilla-Ibarz J.

Core Evid. 2013;8:37-45. doi: 10.2147/CE.S34068. Epub 2013 May 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk